Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -10.43% is 45% above its 5-year average of -18.88%, around the middle of its 5-year range (-54.27%–23.00%).
749.31% below its 12-month average of -1.23%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -7.84%.
EBITDA MARGIN
-10.43%
EBITDA MARGIN AVG TTM
-1.23%
EBITDA MARGIN AVG 3Y
-18.78%
EBITDA MARGIN AVG 5Y
-18.88%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-749.31%
CURRENT VS 3Y AVG
+44.46%
CURRENT VS 5Y AVG
+44.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
10x Genomics, Inc.
Market Cap
$10.54B
EBITDA Margin
-10.43%
TTM Avg
-1.23%
3Y Avg
-18.78%
5Y Avg
-18.88%
Market Cap
$10.69B
EBITDA Margin
15.05%
TTM Avg
14.69%
3Y Avg
13.35%
5Y Avg
14.10%
Market Cap
$10.72B
EBITDA Margin
-29.58%
TTM Avg
-45.05%
3Y Avg
-68.49%
5Y Avg
-88.34%
Market Cap
$10.35B
EBITDA Margin
20.41%
TTM Avg
18.54%
3Y Avg
20.94%
5Y Avg
21.85%
Market Cap
$10.35B
EBITDA Margin
-212.29%
TTM Avg
-1213.73%
3Y Avg
-49114.16%
5Y Avg
-44116.26%
Market Cap
$10.87B
EBITDA Margin
19.03%
TTM Avg
19.69%
3Y Avg
15.98%
5Y Avg
11.44%
Market Cap
$10.14B
EBITDA Margin
19.75%
TTM Avg
19.29%
3Y Avg
19.87%
5Y Avg
21.06%
Market Cap
$10.13B
EBITDA Margin
2.15%
TTM Avg
3.41%
3Y Avg
4.20%
5Y Avg
4.49%
Market Cap
$10.97B
EBITDA Margin
27.02%
TTM Avg
27.38%
3Y Avg
26.41%
5Y Avg
26.36%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 10x Genomics, Inc. (TXG) | $10.54B | -10.43% | -1.23% | -18.78% | -18.88% |
| Universal Health Services, Inc. (UHS)vs › | $10.69B | 15.05% | 14.69% | 13.35% | 14.10% |
| Twist Bioscience Corporation (TWST)vs › | $10.72B | -29.58% | -45.05% | -68.49% | -88.34% |
| Globus Medical, Inc. (GMED)vs › | $10.35B | 20.41% | 18.54% | 20.94% | 21.85% |
| ImmunityBio, Inc. (IBRX)vs › | $10.35B | -212.29% | -1213.73% | -49114.16% | -44116.26% |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.87B | 19.03% | 19.69% | 15.98% | 11.44% |
| Align Technology, Inc. (ALGN)vs › | $10.14B | 19.75% | 19.29% | 19.87% | 21.06% |
| Molina Healthcare, Inc. (MOH)vs › | $10.13B | 2.15% | 3.41% | 4.20% | 4.49% |
| The Cooper Companies, Inc. (COO)vs › | $10.97B | 27.02% | 27.38% | 26.41% | 26.36% |
| The Ensign Group, Inc. (ENSG)vs › | $10.06B | 10.47% | 10.43% | 10.38% | 10.85% |
Gross Margin
70.0%
EBITDA Margin
-10.4%
Operating Margin
-14.3%
Net Margin
-12.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -7.84% |
| 2026-03-31 | -3.40% |
| 2025-12-31 | -4.48% |
| 2025-09-30 | -13.42% |
| 2025-06-30 | 23.00% |
| 2025-03-31 | -19.06% |
| 2024-12-31 | -23.80% |
| 2024-09-30 | -20.27% |
| 2024-06-30 | -20.14% |
| 2024-03-31 | -35.46% |
| 2023-12-31 | -23.63% |
| 2023-09-30 | -54.27% |
| 2023-06-30 | -35.06% |
| 2023-03-31 | -32.30% |
| 2022-12-31 | -9.36% |
| 2022-09-30 | -24.32% |
| 2022-06-30 | -47.70% |
| 2022-03-31 | -29.49% |
| 2021-12-31 | -5.93% |
| 2021-09-30 | -6.87% |
| 2021-06-30 | -2.71% |
| 2021-03-31 | -3.54% |
| 2020-12-31 | -360.16% |
| 2020-09-30 | -84.07% |
| 2020-06-30 | -81.46% |
| 2020-03-31 | -21.73% |
| 2019-12-31 | -6.95% |
| 2019-09-30 | -11.53% |
| 2019-06-30 | -16.51% |
| 2019-03-31 | -3.73% |
| 2018-12-31 | -146.53% |
| 2018-09-30 | -38.48% |
| 2018-06-30 | -13.76% |
| 2018-03-31 | -21.12% |
